RNAi技術と世界市場

世界のRNAi技術の市場規模は、2023年の21億米ドルから、予測期間中はCAGR 14.8%で推移し、2029年には48億米ドルに達すると予測されています。

治療薬の部門は、2023年の16億米ドルから、CAGR 16.2％で推移し、2029年には39億米ドルに達すると予測されています。また、ツール・試薬の部門は、2023年の5億290万米ドルから、CAGR 9.9%で推移し、2029年には8億8,280万米ドルに達すると予測されています。

当レポートでは、世界のRNAi技術の市場を調査し、市場概要、市場影響因子および市場機会の分析、新興技術および技術開発の動向、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブサマリー

• 市場見通し
• 調査範囲
• 市場概要

第2章 市場概要

• 背景：遺伝物質
• RNA干渉の概要
• RNA干渉：作用機序
• 開始段階
• エフェクターフェーズ
• 低分子干渉RNA (siRNA)
• マイクロRNA (miRNA)
• 小型ヘアピンRNA (shRNA)

第3章 市場力学

• 世界の市場力学
• 市場促進要因
• 市場抑制要因
• 市場機会

第4章 新興技術と開発

• 治療薬
• 診断
• 非侵襲的健康モニタリングのための循環miRNA診断
• 農業

第5章 パイプライン分析

第6章 特許分析

第7章 市場セグメンテーション分析

• セグメンテーションの内訳
• 概要
• 市場分析：技術別
• 治療薬
• RNAi治療薬市場：地域別
• RNAi治療薬市場：治療領域別
• RNAi治療薬市場：投与方法別
• 診断
• 試薬・ツール
• 農業
• 地理的内訳
• 市場分析：地域別
• 北米
• 欧州
• 新興市場

第8章 競合情報

• 戦略的イニシアチブ
• 競合分析

第9章 RNAi技術市場における持続可能性：ESGの観点

• ESG：イントロダクション
• RNAi技術業界における持続可能性：ESGの観点
• 環境への取り組み
• 社会貢献活動
• ガバナンスの取り組み
• ケーススタディ
• BCCからの総論

第10章 付録

• 調査手法
• 略語
• 出典
• 企業プロファイル
• ALNYLAM PHARMACEUTICALS INC.
• ARROWHEAD PHARMACEUTICALS INC.
• ARBUTUS BIOPHARMA CORP.
• BAYER AG
• MERCK KGAA
• NOVARTIS AG
• NOVO NORDISK A/S
• OLIX PHARMACEUTICALS INC.
• QIAGEN
• REVVITY INC.
• SILENCE THERAPEUTICS
• SIRNAOMICS
• SYLENTIS S.A.
• SWITCH THERAPEUTICS
• THERMO FISHER SCIENTIFIC INC.

List of Tables

• Summary Table : Global Market for RNAi Technology, by Technology Type, Through 2029
• Table 1 : Projected Number of Adults 50 Years and Older with >=1 Chronic Condition in the U.S., 2020-2050
• Table 2 : Cost Comparison of siRNA-approved Drugs and Alternative Therapies
• Table 3 : List of Selected Pipeline Molecules
• Table 4 : Selected Patents for RNAi Technology, Published in 2021
• Table 5 : Selected Patents for RNAi Technology, Published in 2022
• Table 6 : Selected Patents for RNAi Technology, Published in 2023
• Table 7 : Selected Patents for RNAi Technology, Published January to April 2024
• Table 8 : Global Market for RNAi Technology, by Technology Type, Through 2029
• Table 9 : RNAi Approved Drugs List
• Table 10 : Global Market for RNAi Therapeutics, by Region, Through 2029
• Table 11 : Global Market for RNAi Therapeutics, by Therapeutic Area, Through 2029
• Table 12 : Global Market for RNAi Therapeutics, by Delivery Method, Through 2029
• Table 13 : miRNA-based Diagnostic Tools Available in Clinical Settings
• Table 14 : Global Market for RNAi Diagnostics, by Region, Through 2029
• Table 15 : Global Market for RNAi Reagents and Tools, by Type, Through 2029
• Table 16 : Global Market for RNAi Reagents and Tools, by Region, Through 2029
• Table 17 : Global Market for RNAi Research Tools and Constructs, by Region, Through 2029
• Table 18 : Global Market for RNAi Reagents, by Region, Through 2029
• Table 19 : Global Market for RNAi Agriculture, by Region, Through 2029
• Table 20 : Global Market for RNAi Technology, by Region, Through 2029
• Table 21 : Strategic Initiatives in Global RNAi Technology Market, 2020-2024
• Table 22 : Global Rankings of Top RNAi Reagents and Tools Manufacturers, 2022
• Table 23 : Key Focus Areas in ESG Metrices
• Table 24 : Environmental Initiatives, by Various RNAi Technology Companies
• Table 25 : ESG Rankings for Companies in the RNAi Technology Market, 2023
• Table 26 : Alnylam's ESG initiatives
• Table 27 : Glossary of Terms Used in This Report
• Table 28 : Report Information Sources
• Table 29 : Alnylam Pharmaceuticals Inc.: Company Snapshot
• Table 30 : Alnylam Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
• Table 31 : Alnylam Pharmaceuticals Inc.: Product Portfolio
• Table 32 : Alnylam Pharmaceuticals Inc.: News/Key Developments, 2023
• Table 33 : Arrowhead Pharmaceuticals Inc.: Company Snapshot
• Table 34 : Arrowhead Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
• Table 35 : Arrowhead Pharmaceuticals Inc.: News/Key Developments, 2021-2024
• Table 36 : Arbutus BioPharma Corp.: Company Snapshot
• Table 37 : Arbutus Biopharma Corp.: Financial Performance, FY 2022 and 2023
• Table 38 : Arbutus BioPharma Corp.: News/Key Developments, 2021-2023
• Table 39 : Bayer AG: Company Snapshot
• Table 40 : Bayer AG: Financial Performance, FY 2022 and 2023
• Table 41 : Bayer AG: Product Portfolio
• Table 42 : Bayer AG: News/Key Developments, 2023
• Table 43 : Merck KGaA: Company Snapshot
• Table 44 : Merck KGaA: Financial Performance, FY 2022 and 2023
• Table 45 : Merck KGaA.: Product Portfolio
• Table 46 : Merck KGaA: News/Key Developments, 2021-2024
• Table 47 : Novartis AG: Company Snapshot
• Table 48 : Novartis AG: Financial Performance, FY 2022 and 2023
• Table 49 : Novartis AG: Product Portfolio
• Table 50 : Novartis AG: News/Key Developments, 2020-2024
• Table 51 : Novo Nordisk A/S: Company Snapshot
• Table 52 : Novo Nordisk A/S: Financial Performance, FY 2022 and 2023
• Table 53 : Novo Nordisk A/S: Product Portfolio
• Table 54 : Novo Nordisk A/S: News/Key Developments, 2021-2023
• Table 55 : OliX Pharmaceuticals Inc.: Company Snapshot
• Table 56 : OliX Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
• Table 57 : OliX Pharmaceuticals Inc.: News/Key Developments, 2019-2023
• Table 58 : Qiagen: Company Snapshot
• Table 59 : Qiagen: Financial Performance, FY 2022 and 2023
• Table 60 : Qiagen: Product Portfolio
• Table 61 : Qiagen: News/Key Developments, 2023
• Table 62 : Revvity Inc.: Company Snapshot
• Table 63 : Revvity Inc.: Financial Performance, FY 2022 and 2023
• Table 64 : Revvity Inc.: Product Portfolio
• Table 65 : Revvity Inc.: News/Key Developments, 2023 and 2024
• Table 66 : Silence Therapeutics: Company Snapshot
• Table 67 : Silence Therapeutics: Financial Performance, FY 2022 and 2023
• Table 68 : Silence Therapeutics: News/Key Developments, 2022 and 2023
• Table 69 : Sirnaomics: Company Snapshot
• Table 70 : Sirnaomics: Financial Performance, FY 2022 and 2023
• Table 71 : Sirnaomics: News/Key Developments, 2023
• Table 72 : Sylentis S.A.: Company Snapshot
• Table 73 : Sylentis S.A.: News/Key Developments, 2023
• Table 74 : Switch Therapeutics: Company Snapshot
• Table 75 : Thermo Fisher Scientific Inc.: Company Snapshot
• Table 76 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
• Table 77 : Thermo Fisher Scientific Inc.: Product Portfolio
• Table 78 : Thermo Fisher Scientific Inc.: News/Key Developments, 2021-2023

List of Figures

• Summary Figure : Global Market for RNAi Technology, by Technology Type, 2021-2029
• Figure 1 : RNAi Pathway
• Figure 2 : Market Dynamics of RNAi Technology
• Figure 3 : Tissues Targeted by RNAi Therapeutics
• Figure 4 : Patents Documented Over Time, 2010-April 2024
• Figure 5 : Global Market for RNAi Technology, by Technology Type, 2021-2029
• Figure 6 : Global Market Shares of RNAi Technology, by Technology Type, 2023
• Figure 7 : RNAi Therapeutics Timeline, 1998-2023
• Figure 8 : Global Market for RNAi Therapeutics, by Region, 2021-2029
• Figure 9 : Global Market for RNAi Therapeutics, by Therapeutic Area, 2021-2029
• Figure 10 : Global Market for RNAi Therapeutics, by Delivery Method, 2021-2029
• Figure 11 : MicroRNA (miRNA) Biomarkers in Various Cancers
• Figure 12 : Global Market for RNAi Diagnostics, by Region, 2021-2029
• Figure 13 : Global Market for RNAi Reagents and Tools, by Type, 2021-2029
• Figure 14 : Global Market for RNAi Reagents and Tools, by Region, 2021-2029
• Figure 15 : Global Market for RNAi Research Tools and Constructs, by Region, 2021-2029
• Figure 16 : Global Market for RNAi Reagents, by Region, 2021-2029
• Figure 17 : Global Market for RNAi Agriculture, by Region, 2021-2029
• Figure 18 : Global Market for RNAi Technology, by Region, 2021-2029
• Figure 19 : Global Market Shares of RNAi Technology, by Region, 2023
• Figure 20 : Global Market Shares of RNAi Technology, by Suppliers/Manufacturers, 2023
• Figure 21 : Research Communities' Key Sustainable Practices in Research Laboratories
• Figure 22 : Alnylam Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 23 : Alnylam Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 24 : Bayer AG: Revenue Share, by Business Unit, FY 2023
• Figure 25 : Bayer AG: Revenue Share, by Country/Region, FY 2023
• Figure 26 : Merck KGaA: Revenue Share, by Business Unit, FY 2023
• Figure 27 : Merck KGaA: Revenue Share, by Country/Region, FY 2023
• Figure 28 : Novartis AG: Revenue Share, by Business Unit, FY 2023
• Figure 29 : Novartis AG: Revenue Share, by Country/Region, FY 2023
• Figure 30 : Novo Nordisk A/S: Revenue Share, by Business Unit, FY 2023
• Figure 31 : Novo Nordisk A/S: Revenue Share, by Country/Region, FY 2023
• Figure 32 : Qiagen: Revenue Share, by Business Unit, FY 2023
• Figure 33 : Qiagen: Revenue Share, by Country/Region, FY 2023
• Figure 34 : Revvity Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 35 : Revvity Inc.: Revenue Share, by Country/Region, FY 2023
• Figure 36 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2023
• Figure 37 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2023

The global market for RNAi technology is estimated to increase from $2.1 billion in 2023 to reach $4.8 billion by 2029, at a compound annual growth rate (CAGR) of 14.8% from 2024 through 2029.

The therapeutics market for RNAi technology is estimated to increase from $1.6 billion in 2023 to reach $3.9 billion by 2029, at a CAGR of 16.2% from 2024 through 2029.

The tools and reagents market for RNAi technology is estimated to increase from $502.9 million in 2023 to reach $882.8 million by 2029, at a CAGR of 9.9% from 2024 through 2029.

Report Scope

The scope of this study encompasses an investigation of the ribonucleic acid interference (RNAi) technology market. BCC Research analyzes RNAi technology based on technology type: tools and reagents, diagnostics, therapeutics, and agriculture. BCC Research determines the current market status in each segment, examines its impact on future needs, and presents growth forecasts over the next six years. The report provides a detailed analysis of the market's drivers, restraints, challenges, and opportunities. It includes company profiles of key players, with detailed information about their business segments, financials, product portfolios, and recent developments. The report also provides detailed information on emerging technologies and new developments in the market; examines the regulatory landscape; provides a patent and pipeline analysis; and discusses ESG developments, the investment outlook, and deals within the market.

Report Includes

• 26 data tables and 53 additional tables
• An overview of the global market for RNAi technologies
• Analysis of global market trends, featuring revenue data for 2021- 2023, estimated figures for 2024, forecasts for 2029, and projected CAGRs through 2029
• Evaluation of the current market's size and revenue growth prospects, along with a market share analysis by type, therapeutic area, delivery method, and region
• A look at innovations, technological advances, and recent product launches in the RNAi market
• Analysis of the industry's regulatory framework and policies
• A discussion of ESG challenges and ESG practices in the RNAi technologies industry
• An analysis of the key companies' market shares, proprietary technologies, and strategic alliances
• Company profiles of major players within the industry, including Alnylam Pharmaceuticals Inc., Novartis AG, Thermo Fisher Scientific Inc., and Revvity Inc.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Background: Genetic Material
• RNA Interference Overview
• RNA Interference: Mechanism of Action
• Initiation Phase
• Effector Phase
• Small Interfering RNAs (siRNAs)
• MicroRNAs (miRNAs)
• Small Hairpin RNAs (shRNAs)

Chapter 3 Market Dynamics

• Global Market Dynamics
• Market Drivers
• Increasing Prevalence of Chronic Disease
• Increasing Approval of RNAi Products
• Advancements in RNAi Delivery Systems
• Increasing Strategic Initiatives
• Convenient Dosing
• Market Restraints
• High Treatment Costs
• Lack of Awareness
• Market Opportunities
• Expansion of Disease Targets
• Combination Therapies
• Untapped Genetic Targets

Chapter 4 Emerging Technologies and Developments

• Therapeutics
• Diagnostics
• Circulating miRNA Diagnostics for Non-invasive Health Monitoring
• Agriculture

Chapter 5 Pipeline Analysis

Chapter 6 Patent Analysis

• Patent Analysis

Chapter 7 Market Segmentation Analysis

• Segmentation Breakdown
• Overview
• Market Analysis by Technology
• Therapeutics
• RNAi Therapeutics Market, by Region
• RNAi Therapeutics Market, by Therapeutic Area
• RNAi Therapeutics Market, by Delivery Method
• Diagnostics
• Reagents and Tools
• Agriculture
• Geographic Breakdown
• Market Analysis by Region
• North America
• Europe
• Emerging Markets

Chapter 8 Competitive Intelligence

• Strategic Initiatives
• Competitive Analysis

Chapter 9 Sustainability in RNAi Technology Market: An ESG Perspective

• Introduction to ESG
• Sustainability in RNAi Technology Industry: An ESG Perspective
• Environmental Initiatives
• Social Initiatives
• Governance Initiatives
• Case Study
• Concluding Remarks from BCC

Chapter 10 Appendix

• Methodology
• Acronyms
• Sources
• Company Profiles
• ALNYLAM PHARMACEUTICALS INC.
• ARROWHEAD PHARMACEUTICALS INC.
• ARBUTUS BIOPHARMA CORP.
• BAYER AG
• MERCK KGAA
• NOVARTIS AG
• NOVO NORDISK A/S
• OLIX PHARMACEUTICALS INC.
• QIAGEN
• REVVITY INC.
• SILENCE THERAPEUTICS
• SIRNAOMICS
• SYLENTIS S.A.
• SWITCH THERAPEUTICS
• THERMO FISHER SCIENTIFIC INC.